You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. System for the Large-scale Production of Membrane Proteins

    SBC: Athena Environmental Sciences Inc            Topic: 400

    Membrane proteins play a fundamental and critical role in cellular processes. Their direct link to human disease as well as their key role in signal transduction, has made many membrane proteins the foremost targets for chemotherapeutic intervention with more than 50% of all drugs designed to modulate the activity of this class of proteins. Despite this central role in human health, the biochemica ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Universal Immunotherapeutic for Influenza Viruses

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Influenza virus (INFV) results in global seasonal and pandemic outbreaks estimated to cause severe illness in 3 to 5 million people annually resulting in significant morbidity and up to 650,000 deaths. The influenza burden also results in substantial economic loss. The goal of this program is to develop a therapeutic antibody offering effective treatment with broad heterosubtypic s ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Low Cost Carbon Dioxide-Based Cryoablation for Breast Cancer Treatment in Low Resource Settings

    SBC: KUBANDA CRYOTHERAPY            Topic: 102

    Summary The principal goal of this proposal is to demonstrate equivalence in efficacy of CO2- based percutaneous cryotherapy compared to commercial argon-based devices in order to improve the accessibility of a novel low-cost breast cancer treatment device for women in low-resource areas. Breast cancer is the leading cause of cancer death among women worldwide. Though more than 800,000 women are d ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Novel Chemokine Receptor Antagonist Peptide as a Non-Opioid Treatment for Relief of Chronic Pain

    SBC: CREATIVE BIO-PEPTIDES INC            Topic: 106

    7. Project Summary In response to RFS-NS-20-11, Creative Bio-Peptides, Inc. will develop the multi-chemokine receptor antagonist peptide R103 to provide a non-opioid, potentially disease modifying treatment for neuropathic pain conditions. We have completed proof-of-concept (POC) animal studies in neuropathic pain by partial nerve ligation and diabetes. We will conduct a further POC study of R103 ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy

    SBC: ONCOC4, INC.            Topic: 102

    Summary A major paradigm in cancer immunotherapy is to use checkpoint inhibitors to break regulatory mechanisms that guard the host against autoimmune diseases. CTLA-4-targeting immunotherapy was the first example to establish this paradigm. However, the clinically tested anti-CTLA-4 antibodies exhibit suboptimal efficacy but high toxicity. Our preclinical study demonstrate that this outcome is pr ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Portable Ankle Robotics to Reverse Foot Drop After Stroke.

    SBC: NEXTSTEP ROBOTICS, INC.            Topic: 105

    This proposal finalizes the design of a portable ankle robot as a therapeutic device to reverse foot drop and restore safer independent walking after stroke, then conducts a rigorous randomized clinical trial to establish clinical proof for this new market application. Currently, there are no therapeutic solutions for foot-drop, only assistive devices (braces, canes, electrical stimulation) that d ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. A Yeast-based Immunotherapy against Clostridioides difficile infection

    SBC: FZATA INC            Topic: NIAID

    Abstract Antibiotic-resistant Clostridioides difficile is responsible for more than 29,000 deaths in the US each year and the infection is an urgent threat (as designated by CDC) to public health. The incidence of C. difficile infection (CDI) and disease severity is increasing in recent years due to the emergence of hypervirulent and antibiotic- resistant strains. CDI is caused by the exotoxins Tc ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Treg-depleting immunotherapy

    SBC: SONOVAL LLC            Topic: 102

    Abstract Sonoval is expanding its successful biologic drug platform technology to develop second generation versions of the cancer therapeutic Ontak, with the potential to advance the field of regulatory T cells (Tregs)-depleting immunotherapy through a mechanism previously unique to Ontak alone. Sonova;’s therapeutics will target Tregs for treatment of major solid tumors, which afflict rt50,000 ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Probiotic for the Treatment of Sjogren's Syndrome

    SBC: Rise Therapeutics, LLC            Topic: NIDCR

    Project Summary Our goal is to develop a novel, immunologically enhanced L. lactis probiotic-based therapeutic for the treatment of Sjögren’s Syndrome (SjS). SjS is a progressive, chronic autoimmune disease characterized by inflammatory cell infiltration of the salivary and lacrimal glands, resulting in acinar epithelial cell atrophy, cell death, and loss of exocrine function 1-6. At least half ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)

    SBC: FZATA INC            Topic: 300

    Abstract Ulcerative colitis and Crohn’s disease are major forms of inflammatory bowel disease (IBD), which is characterized by chronic intestinal inflammation and gut microbiota dysbiosis. IBD has been associated with poor quality of life and often results in complications requiring hospitalizations and surgical procedures that causes significant morbidity and financial losses in the US. In past ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government